Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947262 | 1.00 | MAPT (0.51) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12136703 | 0.89 | MAPT (0.52) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12136699 | 0.89 | MAPT (0.52) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12658257 | 0.88 | MAPT (0.49) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12658258 | 0.87 | MAPT (0.48) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL13125298 | 0.84 | ALDH1A1 (0.57) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12658341 | 0.83 | ALDH1A1 (0.51) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12136709 | 0.80 | MAPT (0.65) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12136707 | 0.79 | MAPT (0.47) | MAPTALDH1A1HTTKDM4EMAPK1 | |
| SCHEMBL12569502 | 0.79 | ALDH1A1 (0.62) | MAPTALDH1A1HTTKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9017701-B2 | Organogel compositions comprising alkylated benzimidazolones | XEROX CORPORATION (US) | 2015-04-28 | — | — | US | disclosed |
| US-20130123375-A1 | Organogel Compositions Comprising Alkylated Benzimidazolones | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123375-A1 | Organogel Compositions Comprising Alkylated Benzimidazolones | BLM, SBK3, CHEK2 | MAPT 1891/4885ALDH1A1 1114/4885HTT 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.